Skip to main content
SpringerLink
Log in

Statins and Demyelination

  • Chapter
Advances in multiple Sclerosis and Experimental Demyelinating Diseases

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 318))

Statins are inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase, which are widely prescribed for their cholesterol-lowering properties in order to reduce atherogenesis and cardiovascular morbidity. Moreover, statins have been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. Statins appear to alter immune function largely independent of lipid lowering and rather through inhibition of posttranslational protein prenylation of small regulatory GTP-binding proteins. In experimental autoimmune encephalomyelitis (EAE), the murine model for multiple sclerosis (MS), statins were shown to reverse established paralysis and to exert synergistic benefit in combination with agents approved for MS therapy. Based upon these encouraging findings in treatment of EAE, statins are now being tested in clinical trials in patients with MS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anonymous (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 s). Lancet 344: 1383-1389

    Google Scholar 

  2. Anonymous (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. N Engl J Med 339:1349-1357

    Article  Google Scholar 

  3. Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383:787-793

    Article  CAS  PubMed  Google Scholar 

  4. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197:725-733

    Article  CAS  PubMed  Google Scholar 

  5. Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD (1998) Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 161:4437-4446

    CAS  PubMed  Google Scholar 

  6. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F (1998) HMGCOA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18:1671-1678

    CAS  PubMed  Google Scholar 

  7. Birnbaum G, Irfan A (2005) A double blind, placebo controlled combination trial of interferon beta 1a (Rebif) and atorvastatin (Lipitor) in patients with relapsing remitting multiple sclerosis. Paper presented at the AAN, 2005

    Google Scholar 

  8. Bonet S, Garcia Villena I, Tomas Santos P, Tapia Mayor I, Gussinye Canabal P, Mundet Tuduri X (1999) When and how do we treat our hypercholesterolemic patients?. Aten Primaria 24:397-403

    CAS  PubMed  Google Scholar 

  9. Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424-435

    Article  CAS  PubMed  Google Scholar 

  10. Chang CH, Flavell RA (1995) Class ii transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 181:765-767

    Article  CAS  PubMed  Google Scholar 

  11. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA (2000) Glatiramer acetate (Copaxone) induces degenerate, th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105:967-976

    Article  CAS  PubMed  Google Scholar 

  12. Dunn SE, Youssef S, Goldstein MJ, Prod’homme T, Weber MS, Zamvil SS, Steinman L (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203:401-412

    Article  CAS  PubMed  Google Scholar 

  13. Dustin ML, Shaw AS (1999) Costimulation: building an immunological synapse. Science 283:649-650

    Article  CAS  PubMed  Google Scholar 

  14. Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH (2001) Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 56:931-933

    Article  CAS  PubMed  Google Scholar 

  15. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH (2002) Statins and risk of polyneuropathy: a case-control study. Neurology 58:1333-1337

    CAS  PubMed  Google Scholar 

  16. Ganne F, Vasse M, Beaudeux JL, Peynet J, Francois A, Mishal Z, Chartier A, Tobelem G, Vannier JP, Soria J, Soria C (2000) Cerivastatin, an inhibitor of HMG-COA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb Haemost 84:680-688

    CAS  PubMed  Google Scholar 

  17. Ginsberg HN (1998) Effects of statins on triglyceride metabolism. Am J Cardiol 81:32B-35B

    Article  CAS  PubMed  Google Scholar 

  18. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585-2590

    Article  CAS  PubMed  Google Scholar 

  19. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P (2003) Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 17:905-907

    CAS  PubMed  Google Scholar 

  20. Ifergan I, Wosik K, Cayrol R, Kebir H, Auger C, Bernard M, Bouthillier A, Moumdjian R, Duquette P, Prat A (2006) Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 60:45-55

    Article  CAS  PubMed  Google Scholar 

  21. Jorritsma PJ, Brogdon JL, Bottomly K (2003) Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells. J Immunol 170:2427-2434

    CAS  PubMed  Google Scholar 

  22. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI et al (1995) Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540

    CAS  PubMed  Google Scholar 

  23. Khoury SJ, Hancock WW, Weiner HL (1992) Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 176:1355-1364

    Article  CAS  PubMed  Google Scholar 

  24. Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y, Jalili F, Bar-Or A (2004) Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 172:7144-7153

    CAS  PubMed  Google Scholar 

  25. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA et al (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627

    Article  CAS  PubMed  Google Scholar 

  26. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177:566-573

    CAS  PubMed  Google Scholar 

  27. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402

    Article  CAS  PubMed  Google Scholar 

  28. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015-2021

    Article  CAS  PubMed  Google Scholar 

  29. Menge T, Hartung HP, Stuve O (2005) Statins - a cure-all for the brain? Nat Rev Neurosci 6:325-331

    Article  CAS  PubMed  Google Scholar 

  30. Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP (2007) Simvastatin regulates oligodendroglial process dynamics and survival. Glia 55:130-143

    Article  PubMed  Google Scholar 

  31. Mix E, Ibrahim SM, Pahnke J, Glass A, Mazon-Pelaez I, Lemcke S, Koczan D, Gimsa U, Bansemer S, Scheel T, Karopka T, Bottcher T, Muller J, Dazert E, Antipova V, Hoffrogge R, Wree A, Zschiesche M, Strauss U, Kundt G, Warzok R, Gierl L, Rolfs A (2006) 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. J Autoimmun 27:251-265

    Article  CAS  PubMed  Google Scholar 

  32. Nath N, Giri S, Prasad R, Singh AK, Singh I (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy. J Immunol 172:1273-1286

    CAS  PubMed  Google Scholar 

  33. Neuhaus O, Farina C, Wekerle H, Hohlfeld R (2001) Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702-708

    CAS  PubMed  Google Scholar 

  34. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990-997

    Article  CAS  PubMed  Google Scholar 

  35. Pahan K, Sheikh FG, Namboodiri AM, Singh I (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100:2671-2679

    Article  CAS  PubMed  Google Scholar 

  36. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I (2005) HMG-COA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J 19:1407-1421

    Article  CAS  PubMed  Google Scholar 

  37. Paintlia AS, Paintlia MK, Singh I, Singh AK (2006) Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta- d- ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol 169:1012-1025

    Article  CAS  PubMed  Google Scholar 

  38. Sadeghi MM, Tiglio A, Sadigh K, O’Donnell L, Collinge M, Pardi R, Bender JR (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-COA reductase inhibitors. Transplantation 71:1262-1268

    Article  CAS  PubMed  Google Scholar 

  39. Schulz JG, Bosel J, Stoeckel M, Megow D, Dirnagl U, Endres M (2004) HMG-COA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem 89:24-32

    Article  CAS  PubMed  Google Scholar 

  40. Sena A, Pedrosa R, Graca Morais M (2003) Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 250:754-755

    Article  CAS  PubMed  Google Scholar 

  41. Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540

    Article  PubMed  Google Scholar 

  42. Stanislaus R, Gilg AG, Singh AK, Singh I (2002) Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by lovastatin. Neurosci Lett 333:167-170

    Article  CAS  PubMed  Google Scholar 

  43. Steinman L (2004) Immune therapy for autoimmune diseases. Science 305:212-216

    Article  CAS  PubMed  Google Scholar 

  44. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod’homme T, Sobel RA, Steinman L, Zamvil SS (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116:1037-1044

    Article  CAS  PubMed  Google Scholar 

  45. Stüve O, Youssef S, Weber MS, Prod’homme T, Dunn SE, Steinman L, Zamvil SS (2004) The combination of atorvastatin and glatiramer acetate induces a Th2 phenotype and shows enhanced clinical efficacy in experimental autoimmune encephalomyelitis. J Neuroimmunol 154:77

    Google Scholar 

  46. Takai Y, Sasaki T, Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81:153-208

    CAS  PubMed  Google Scholar 

  47. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608

    Article  CAS  PubMed  Google Scholar 

  48. Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, Zipp F (2005) Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 174:5630-5635

    CAS  PubMed  Google Scholar 

  49. Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C (2004) Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127:1370-1378

    Article  PubMed  Google Scholar 

  50. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692

    Article  CAS  PubMed  Google Scholar 

  51. Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, Ludwig J, Berger T, Steinkasserer A, Daniel WG, Garlichs CD (2004) HMG-COA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172:85-93

    Article  CAS  PubMed  Google Scholar 

  52. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21:75-80

    Article  CAS  PubMed  Google Scholar 

  53. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS (2002) The HMG-COA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84

    Article  CAS  PubMed  Google Scholar 

  54. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T (2003) 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23:11104-11111

    CAS  PubMed  Google Scholar 

  55. Zeinstra E, Wilczak N, Chesik D, Glazenburg L, Kroese FG, De Keyser J (2006) Simvastatin inhibits interferon-gamma-induced MHC class II up-regulation in cultured astrocytes. J Neuroinflammation 3:16

    Article  PubMed  Google Scholar 

  56. Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of California, San Francisco, 513 Parnassus Avenue, S-268, San Francisco, CA 94143-0435, USA

    M. S. Weber & S. S. Zamvil

Authors
  1. M. S. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. S. Zamvil
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology and Immunology, Mayo Clinic, College of Medicine, 200 First Street SW, Rochester, MN 55905, USA

    Moses Rodriguez

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Weber, M.S., Zamvil, S.S. (2008). Statins and Demyelination. In: Rodriguez, M. (eds) Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology, vol 318. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73677-6_12

Download citation

Publish with us

Policies and ethics

Search

Navigation